May 2003
Worldwide Biotech;May2003, Vol. 15 Issue 5, p1
Trade Publication
Reports on the agreement signed by Oncomab Ltd, a subsidiary of Prima BioMed Ltd., with U.S. antibody company Medarex Inc. to co-develop fully human monoclonal antibodies for treating cancer and to jointly commercialize any resulting antibody products.


Related Articles

  • PHARMATHENE TO GET UP TO $13.9 MIL FOR ANTHRAX ANTI-TOXIN.  // Biotech Business;Nov2007, Vol. 20 Issue 11, p4 

    The article reports that PharmAthene Inc. and Medarex Inc. have announced that the U.S. National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority has awarded PharmAthene a contract for the advanced development of Valortim, a fully human...

  • Medarex Sharing up to $225M in Antibody Deal.  // Bioworld Week;4/27/2009, Vol. 17 Issue 17, p3 

    The article reports on the $225 million licence deal between Merck & Co. Inc. as well as Medarex Inc. and Massachusetts Biologic Laboratories regarding the combined monoclonal antibodies developed by the latter companies. It says that the deal enables Merck to gain worldwide rights to develop...

  • Deal watch: Monoclonal antibodies targeting Clostridium difficile licensed to Merck.  // Nature Reviews Drug Discovery;Jun2009, Vol. 8 Issue 6, p442 

    The article analyzes the licensing agreement that Merck & Co. Inc. has signed for an investigational human monoclonal antibody (mAb) combination, co-developed by Medarex Inc. and Massachusetts Biological Laboratories (MBL) for the treatment of Clostridium difficile (C. difficile) infection. The...

  • Hendra virus treatment moves forward in Australia.  // DVM: The Newsmagazine of Veterinary Medicine;Oct2010, Vol. 41 Issue 10, p30 

    The article reports on the agreement to produce the Hendra monoclonal antibody at the University of Queensland in Brisbane which was first developed in Washington by the Commonwealth Scientific and Industrial Research Organisation's Australian Animal Health Laboratory.

  • The Anthrax Arsenal Takes Shape. Quinn, William T. // njbiz;10/25/2004, Vol. 17 Issue 42, p14 

    Discusses the efforts of New Jersey companies to develop vaccines or drug therapies in preparation for future anthrax attacks, as of October 2004. Information on law signed by U.S. President George W. Bush enacting Project BioShield to secure funding for drug research; Effect of antibiotics and...

  • Medarex Sharing up to $225M from Antibody Deal with Merck. Hollingsworth, Catherine // BioWorld Today;4/22/2009, Vol. 20 Issue 76, p1 

    The article reports on the licensing of a combination of monoclonal antibodies co-developed by Medarex Inx. and Massachusetts Biologic Laboratories to drug company Merck & Co. Inc. in a deal worth $225 million (M). The deal gave Merck the worldwide righst to develop and commercialize CDA-1 and...

  • Cytos and Medarex expand collaboration.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p15 

    Reports that Swiss biotech firm, Cytos Biotechnology AG and antibody-based therapeutics developer, Medarex have expanded the scope of their collaborative research, development and license agreement for new drug targets. Inclusion of drug targets discovered in other disease areas of interest;...

  • 'Rat' Gain: OMT Developing Alternative to Mouse mAbs. Boggs, Jennifer // BioWorld Today;8/13/2012, Vol. 23 Issue 156, p1 

    The article reports on the development of a fully human monoclonal antibody platform based on transgenic rats by Open Monoclonal Technologies Inc. (OMT). Animal-based antibody platforms have been proven successful and advantageous in that they are easier to manufacture. Mouse antibody platforms...

  • Ipilimumab.  // Drugs in R&D;2010, Vol. 10 Issue 2, p97 

    Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDXCTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics